KR102549063B1 - 췌관 선암종의 검출 및 치료를 위한 방법 - Google Patents

췌관 선암종의 검출 및 치료를 위한 방법 Download PDF

Info

Publication number
KR102549063B1
KR102549063B1 KR1020197019752A KR20197019752A KR102549063B1 KR 102549063 B1 KR102549063 B1 KR 102549063B1 KR 1020197019752 A KR1020197019752 A KR 1020197019752A KR 20197019752 A KR20197019752 A KR 20197019752A KR 102549063 B1 KR102549063 B1 KR 102549063B1
Authority
KR
South Korea
Prior art keywords
delete delete
antigen
timp1
lrg1
pdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197019752A
Other languages
English (en)
Korean (ko)
Other versions
KR20190101395A (ko
Inventor
사미르 한나쉬
미켈라 카펠로
아유무 다구치
지딩 펑
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20190101395A publication Critical patent/KR20190101395A/ko
Application granted granted Critical
Publication of KR102549063B1 publication Critical patent/KR102549063B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020197019752A 2016-12-15 2017-12-15 췌관 선암종의 검출 및 치료를 위한 방법 Active KR102549063B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662435020P 2016-12-15 2016-12-15
US201662435024P 2016-12-15 2016-12-15
US62/435,024 2016-12-15
US62/435,020 2016-12-15
PCT/US2017/066851 WO2018112428A1 (en) 2016-12-15 2017-12-15 Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Publications (2)

Publication Number Publication Date
KR20190101395A KR20190101395A (ko) 2019-08-30
KR102549063B1 true KR102549063B1 (ko) 2023-06-28

Family

ID=62559366

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019752A Active KR102549063B1 (ko) 2016-12-15 2017-12-15 췌관 선암종의 검출 및 치료를 위한 방법

Country Status (6)

Country Link
US (3) US20200182876A1 (enExample)
EP (1) EP3555628A4 (enExample)
JP (3) JP2020514689A (enExample)
KR (1) KR102549063B1 (enExample)
CN (1) CN110121647A (enExample)
WO (1) WO2018112428A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064940B1 (en) * 2013-10-28 2019-07-03 Salivatech Co., Ltd. Salivary biomarker for pancreatic cancer
CN110646554B (zh) * 2019-09-12 2022-05-13 北京博远精准医疗科技有限公司 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用
RU2745793C1 (ru) * 2020-02-26 2021-04-01 Государственное бюджетное учреждение здравоохранения города Москвы городская клиническая больница имени С.П. Боткина департамента здравоохранения города Москвы (ГБУЗ ГКБ им. С.П. Боткина ДЗМ) Способ расчета средней продолжительности жизни у пациентов с метастатической аденокарциномой поджелудочной железы
CN115125312B (zh) * 2021-03-26 2025-07-18 中国科学院上海营养与健康研究所 用于Basal型胰腺导管腺癌(PDAC)诊断的标志物组合及其应用
CN113777309A (zh) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 自身抗体在制备胰腺导管腺癌诊断试剂盒中的应用
CN113917008A (zh) * 2021-09-09 2022-01-11 广州济士源生物技术有限公司 质谱检测尿液中代谢物水平的产品在制备用于早期评估肠道息肉和结直肠癌产品中的应用
CN114487201A (zh) * 2022-02-09 2022-05-13 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 鼻咽癌相关尿液标志物组合的检测试剂的应用
AU2023221839A1 (en) * 2022-02-15 2024-08-22 Kite Pharma, Inc. Predicting adverse events from immunotherapy.
WO2024059549A2 (en) * 2022-09-12 2024-03-21 Board Of Regents, The University Of Texas System Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
US20120202188A1 (en) * 2009-10-01 2012-08-09 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US20160282351A1 (en) * 2013-10-28 2016-09-29 Salivatech Co., Ltd. Salivary biomarkers for cancers, methods and devices for assaying the same, and methods for determining salivary biomarkers for cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012343843B2 (en) * 2011-11-30 2018-03-08 Metanomics Health Gmbh Device and methods to diagnose pancreatic cancer
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
AU2014368412A1 (en) * 2013-12-20 2016-07-07 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel
KR20160045547A (ko) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
US20120202188A1 (en) * 2009-10-01 2012-08-09 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US20160282351A1 (en) * 2013-10-28 2016-09-29 Salivatech Co., Ltd. Salivary biomarkers for cancers, methods and devices for assaying the same, and methods for determining salivary biomarkers for cancers

Also Published As

Publication number Publication date
US20230324394A1 (en) 2023-10-12
JP2025118850A (ja) 2025-08-13
US20250298025A1 (en) 2025-09-25
EP3555628A1 (en) 2019-10-23
CN110121647A (zh) 2019-08-13
KR20190101395A (ko) 2019-08-30
JP2023055806A (ja) 2023-04-18
JP2020514689A (ja) 2020-05-21
US20200182876A1 (en) 2020-06-11
EP3555628A4 (en) 2020-08-05
WO2018112428A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
KR102549063B1 (ko) 췌관 선암종의 검출 및 치료를 위한 방법
Pan et al. Proteomics analysis of bodily fluids in pancreatic cancer
Tan et al. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer
Pedersen et al. Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics
An et al. Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer
Zhu et al. Identification of prothymosin alpha (PTMA) as a biomarker for esophageal squamous cell carcinoma (ESCC) by label-free quantitative proteomics and Quantitative Dot Blot (QDB)
CN110291397A (zh) 肺癌的检测和治疗方法
Chinello et al. The proteomic landscape of renal tumors
WO2022189378A1 (en) Ex vivo method for analysing a tissue sample using proteomic profile matching, and its use for the diagnosis, prognosis of pathologies and for predicting response to treatments
EP3071972B1 (en) Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrence
Huh et al. Novel diagnostic biomarkers for high-grade serous ovarian cancer uncovered by data-independent acquisition mass spectrometry
Hadisurya et al. Data-independent acquisition phosphoproteomics of urinary extracellular vesicles enables renal cell carcinoma grade differentiation
CN120188046A (zh) 鉴定胰腺癌的方法
Zhang et al. A simplified and efficient extracellular vesicle-based proteomics strategy for early diagnosis of colorectal cancer
Bhat et al. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan
Chen et al. UHPLC-HRMS-based serum untargeted lipidomics: phosphatidylcholines and sphingomyelins are the main disturbed lipid markers to distinguish colorectal advanced adenoma from cancer
Song et al. MALDI‐TOF‐MS analysis in low molecular weight serum peptidome biomarkers for NSCLC
Kovacevic et al. Urine proteomic analysis in cystinuric children with renal stones
White et al. Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma
Liu et al. Identification of HSP27 as a potential tumor marker for colorectal cancer by the two-dimensional polyacrylamide gel electrophoresis
Piga et al. Paving the path toward multi-omics approaches in the diagnostic challenges faced in thyroid pathology
Vareed et al. Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma
Devasahayam Arokia Balaya et al. An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum
US20220178924A1 (en) Systems and methods for identifying subtype, prognosis, and monitoring of breast cancer
Meleady et al. Proteomic analysis of pancreatic ductal adenocarcinoma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190708

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201214

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220118

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220927

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230328

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230626

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230626

End annual number: 3

Start annual number: 1

PG1601 Publication of registration